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INTRODUCTION
Conventional chemotherapy (with radiotherapy in 
case of localized disease) has made Hodgkin’s lymphoma 
(HL) a curable disease for most of the patients. Salvage 
chemotherapy followed by high dose therapy and 
autologous stem cell transplantation (ASCT) represents 
the treatment of choice for relapsed/refractory (R/R) 
patients, since this therapeutic strategy can provide 
long-term disease control in approximately 50% of R/R 
patients.[1-6] For patients with HL who relapse after 
ASCT, conventional salvage chemotherapies are often 
unsatisfactory. The outcome of this subset of patients is 
rather dismal with a median overall survival (OS) of 2 
years.[7, 8] Relapsed disease after ASCT is considered 
incurable, unless allogeneic transplant (alloSCT) is 
applied. However, very few patients can achieve this goal, 
since refractory disease often hampers the benefits of this 
procedure. 
CD30 is a transmembrane-receptor protein 
expressed on activated B and T lymphocytes and on 
the surface of malignant Hodgkin Reed-Sternberg cells. 
Through CD30-CD30-ligand interaction, eosinophils and 
mast cells may stimulate those malignant cells, promoting 
their survival.[9] Brentuximab vedotin (BV) is a chimeric 
anti-CD30 antibody conjugate via a protease-cleavable 
linker to a microtubule-disrupting agent, monomethyl 
auristatin E. After binding to cell-surface CD30, that agent 
is internalized, traffics to the lysosome and is released 
to disrupt microtubules, inducing cell-cycle arrest and 
apoptosis.[10] Several studies have shown the efficacy of 
BV in patients with HL starting from the pivotal phase II 
study on patients with R/R disease after ASCT, reporting 
a 75% of objective response rate (ORR) with 34% of 
complete response (CR).[11] This high response rate is 
important not only for heavily pretreated patients with a 
poor prognosis, but also for first-line R/R patients, because 
a CR status before the transplant procedure is one of the 
stronger predictors for long-term survival.[12-18] BV 
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ABSTRACT
A large Italian multicenter observational retrospective study was conducted on 
the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin’s lymphoma 
(HL) to check if clinical trial results are confirmed even in a real life context. 234 
CD30+ HL patients were enrolled. Best response was observed after a median of 4 
cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response 
(CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the 
end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was 
higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival 
was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of 
response did not differ for who achieved at least PR and then either did or did not 
undergo consolidative transplant. Overall, the treatment was well tolerated and no 
death has been linked to BV-induced toxicity. 
Our report confirms activity in elderly patients, duration of response unrelated 
to the consolidation with transplant procedure, the relevance of the CR status at first 
restaging, and the role of BV as a bridge to transplant for chemorefractory patients.
Oncotarget3www.impactjournals.com/oncotarget
can represent an optimal therapeutic option as a bridge to 
ASCT or alloSCT in patients who showed a suboptimal 
response after conventional salvage treatment.[15, 19, 
20] Recent updates of the two pivotal studies have shown 
that BV can induce long lasting CR in HL pretreated 
cases either without additional consolidation therapies 
suggesting that BV may lead to a long disease control in 
some patients.[21, 22]
After accelerated approval by US Food and Drug 
Administration, eligible patients in Italy were granted 
early access through a Named Patient Programme (NPP). 
After the closure of NPP, between 2012 and 2014 BV was 
available in Italy for patients with relapsed HL, based 
on a local disposition of the Italian Drug Agency issued 
according to a national law (Law 648/96: “medicinal 
products that are provided free of charge on the national 
health service”): a boundary zone in the passage from 
clinical trials to marketing and free use phases where 
patients can be treated in any case. 
On the basis of our previous explorative study, 
a large Italian observational retrospective study was 
conducted on the use of BV in the everyday clinical 
practice to check if clinical trial results are confirmed even 
in a real life context. [23]
RESULTS
Of the estimated 238 patients who received BV 
under the Law 648/96, 4 (2%) refused to participate in this 
observational study. Characteristics of the 234 patients are 
summarized in Table 1. The median age at BV was 35.4 
years (range, 18-79 years) with 28 (12.0%) elderly patients 
(age≥ 60 years); 129 were males and 105 were females. 
One-hundred-sixteen (49.6%) had systemic symptoms at 
baseline.
The median number of prior treatment regimens 
was 3 (range, 1-6) including high dose chemotherapy 
and ASCT (in 163, 69.6% of the patients). Ninety-eight 
patients (41.9%) had received prior radiation therapy. For 
each patient the status after both frontline therapy and 
most recent therapy was collected: 119 (50.8%) patients 
had disease that was refractory to frontline therapy and 
164 patients (70.1%) had disease that was refractory to last 
therapy before BV. 
Response to treatment
Best response was observed after a median of 4 
cycles in 140 (59.8%) patients: 74 (31.6%) obtained 
a CR and 66 (28.2%) achieved a partial response (PR). 
ORR at the end of the treatment was 48.3% (113 patients) 
represented by 62 (26.5%) CR and 51 (21.7%) PR; among 
the remaining patients, 36 had stable disease (SD), and 85 
patients showed progression of disease (PD), respectively.
The best response rate was higher (p<0.05) in the 
elderly subset (>60 years): 14 (50%) CR and 5 (17.8%) 
PR. In the elderly setting the ORR was 46.4% (13 patients) 
represented by 11 (39.3%) CR and 2 (7.1%) PR. 
We performed analyses to report outcomes of 
patients who underwent stem cell transplant compared to 
those who did not. Patients who had a prior ASCT were 
further considered with two criteria: first we calculated 
overall response rate in patients who underwent ASCT 
any time before brentuximab then in the ones who had 
ASCT immediately before brentuximab. In patients who 
had ASCT any time before brentuximab (n = 163) ORR 
after BV was 53.9% and complete response rate 29.4%. In 
patients who had ASCT immediately before brentuximab 
(n = 89) ORR after BV was 75.3% and CR rate 29.2%. In 
patients who did not undergo ASCT before brentuximab 
(n = 71) ORR after BV was 50.7% and CR rate 25.4%.
Twelve patients who were in CR after 4 cycles 
(the first evaluation as per schedule) relapsed during 
subsequent BV courses; fifteen patients who were in PR 
at the first restaging converted to CR status after further 
four BV infusions. All patients but one who were in SD 
or PD at first restaging did not improve their status at the 
end of therapy. Globally, the median number of cycles 
administered was 6 (range 1-16).
At a median follow up of 18 months OS was 59.8% 
at 55 months (Figure 1), median has not reached yet. 
Global progression free survival (PFS) at 55 months was 
31.9%, the median was achieved at 11 months (Figure 
2). Global disease free survival (DFS) was 26.3% at 29 
months (Figure 3); 14 out of 62 (22.6%) CR patients 
relapsed, whereas 48 patients are in continuous CR (CCR) 
with median duration of response (DoR) of 23.8 months.
Among the responder patients (CR + PR), 38 
patients had a consolidation with transplant (16 ASCT and 
22 alloSCT) next to BV treatment; the estimated PFS at 36 
months as a function of transplant consolidation did not 
show statistically significant difference between patients 
with consolidation (43.7%, median reached at 17.6 
months) vs. patients who did not undergo consolidation 
(30.1, median reached at 9.0 months) (Figure 4). 
Figure 1: Overall survival.
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Currently, there are 18/30 long term responder patients 
(LTR) still in CCR: 7 with consolidative transplant and 11 
without any consolidative procedure. At the latest follow-
up, 172 (73.5%) patients were alive and 62 deceased (47 
due to lymphoma, 14 for other reasons, and 1 for acute 
myeloid leukemia [AML] at 2 months from the end of the 
treatment).
Safety
All patients who received at least one BV infusion 
were included in the safety analysis. In general, the 
treatment was well tolerated and the toxicity profile 
was very similar to the previously published data. One-
hundred-five (44.8%) patients had an early treatment 
discontinuation: 10 due to extrahematologic toxicity, 38 
for bridge to transplant, and 57 due to PD, with 3 deaths. 
Globally only 15 (6.4%) patients performed 16 cycles.
Sixty-nine (29.5%) patients had at least one toxicity. 
Among hematologic side effects, grade 3/4 adverse 
events (AE) were reported in 9 patients: neutropenia (n 
= 7), thrombocytopenia (n = 1), and pancytopenia (n = 
1) all related to BV. Grade 3/4 extrahematologic toxicity 
was observed in 22 patients: 1 pancreatitis (related), 2 
respiratory failures (related), 1 AML, 1 acute respiratory 
distress syndrome and 17 peripheral sensory neuropathies 
(related). Resolution or improvement of peripheral 
neuropathy was observed in 90% of patients with a median 
time to resolution or improvement of 12 weeks. 
Table 1: Patient demographics and characteristics at baseline.
Total population Elderly (≥60)
Patients, N 234 28
Median age, years (range) 35.4 (18.0-79.0) 66.5 (60.2-78.6)
Median time from diagnosis-BV*, years (range) 2.3 (1.0-33) 2.9 (1.0-19.5)
Male, N (%) 129 (55.1) 17 (60.7)
Stage, N (%)
- I/II 
- III
- IV
99 (42.3)
48 (20.5)
87 (37.2)
11 (39.3)
6 (21.4)
11 (39.3)
ECOG† performance status, N (%)
- 0
- 1
- 2
26 (60.5)
17 (39.5)
-
7 (25.0)
16 (57.1)
5 (17.8)
Bulky disease, N (%) 12 (5.1) 1 (3.5)
Bone marrow involvement, N (%) 15 (6.4) 2 (7.1)
Systemic symptoms, N (%) 116 (49.6) 10 (35.7)
- Refractory to most recent therapy, N (%)
- Refractory to first line therapy, N (%)
164 (70.1)
119 (50.8)
16 (57.1)
9 (32.1)
Median number of previous therapies (range) 3 (1-6) 2 (1-6)
Prior autologous stem cell transplant, N (%) 163 (69.8) 11 (39.3)
Prior radiotherapy, N (%) 98 (41.9) 7 (25.0)
*BV: brentuximab vedotin; †ECOG: Eastern Cooperative Oncology Group.
Figure 2: Progression free survival. Figure 3: Disease free survival.
Oncotarget5www.impactjournals.com/oncotarget
DISCUSSION
This retrospective multicenter Italian study on 
234 patients with R/R HL represents one of the two 
larger reports ever published together with the French 
experience.[18] To note, in the French report were 
included also 37/240 (15.4%) patients who had allo-
SCT prior to BV. Our results are in accordance to the 
pivotal phase II study and to the other experiences both 
experimental and observational with an ORR of 59.8% 
and a CR rate of 31.6% in terms of best response, i.e. 
achieved any time during treatment.[12, 14, 16-18, 23, 24] 
Previous published data refer to a NPP. There is 
a boundary zone in the passage from phase III to phase 
IV trials, i.e. from experimental to marketing and free 
use phases: in this zone patients can be treated with 
unapproved drugs by means of NPP, compassionate and 
off-label use and, in Italy as in the present report, under 
request according to Law 648/96. The main difference 
between a NPP and Law 648/96 lies in inclusion/exclusion 
criteria: under Law 648/96 physicians use the drug in a 
wider spectrum of patients with varied underlying diseases 
and a broad range of concomitant medications. Thus, we 
added additional useful information about the management 
of BV in the real life.
No selection bias at all, as BV was prescribed as 
per clinical indication and Centers and patients were 
consecutively enrolled. 
Some interesting considerations about the role of 
BV in everyday clinical practice can be extrapolated. The 
best response rate was higher in the elderly setting (28 
patients with an age >60 years) with an ORR of 67.8% 
and a CR rate of 50% (all in CCR at the latest follow-
up) confirming the high activity of BV in this patients 
subset at the same number of cycles performed [25, 26]. 
The comparison with the report summing up BV clinical 
trials results between 2006 and 2012 shows that in our 
series the clinical response is superior in terms of CR, 
ORR, and CCR.[13, 25] The patients who had a prior 
ASCT (suggesting chemo-sensitivity) had a better ORR 
than those who had not (suggesting chemo-resistance 
and primary refractory disease), while CR rates are 
comparable. This observation provides additional data on 
the activity of BV in refractory patients.
To be in CR after 4 cycles is confirmed very 
important for classifying the patient as a real good 
responder; at the same time, the right number of cycles 
to be performed for evaluating the potential consolidation 
with transplant (in the major part allogeneic transplant) 
or the continuation with BV until the cycle 16 remains 
an open issue, mainly because in case of CR the choice 
between the two options is at the physician discretion. 
Recently, Chen et al., updating on the pivotal phase 
II study, reported that the 5-year PFS was 67% in CR 
patients submitted to allotransplant next to BV versus 
48% in patients who continued treatment after achieving 
CR to BV at the first restaging without any statistically 
significant difference.[11, 22] Moreover, in this update the 
authors reported that 9% of the enrolled study population 
has achieved a long-term remission (exceeding 5 years) 
without any further anti-lymphoma therapy after treatment 
with single agent BV. In our study, the estimated PFS at 
3 years did not show statistically significant difference 
between patients who underwent consolidation (43.7%) 
vs. patients who did not (30.1%). At the time of writing, 
48 (20.5% of all study population) patients were in CCR 
with a median duration of response of 29 months. Thus, 
also in the real life experience these survival outcomes 
showed that a substantial subset of patients among R/R 
HL obtained CR to single agent BV with a long-term 
disease control. Also the length of the follow up denotes 
the potential cure in some patients despite their lymphoma 
history.
An important question remains unanswered: among 
the CR patients, which may benefit from the transplant 
consolidation? In our series there were 30 LTR patients 
and 18 are still in CCR, 7 with consolidative transplant 
next to BV and 11 without any consolidative procedure: 
among these two subsets it was impossible to extrapolate 
any significant clinical characteristic to identify which is 
the best profile to move to a transplant procedure. Our 
study indicated that for patients who obtained a SD or 
PD after 4 cycles the potential conversion rate to PR or 
CR with further BV administrations is close to zero: only 
one patients out of 84 (1.2%) achieved a CR after a SD. 
The final message is that when patients show SD or PD at 
first restaging, they have to be shifted rapidly to another 
treatment. On the other hand, for patients who achieved 
PR after first restaging it could be important to continue 
the treatment: in our series 15/66 (22.7%) patients showed 
a conversion from PR to CR status, suggesting they 
continued to benefit from therapy. 
Another interesting issue is the use of BV as a 
bridge to ASCT for chemorefractory patients: literature 
data in this topic show great promise.[25, 27, 28] In our 
study 16 patients were treated with BV before ASCT due 
to chemorefractoriness and were intended to proceed to 
ASCT. Among them, 8 patients had a response and finally 
8 patients underwent ASCT. The toxicity profile was 
closely similar to the previously published data; no death 
has been linked to BV-induced toxicity.
Figure 4: Progression free survival in patients with 
and without stem cell transplant (SCT) consolidation.
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In conclusion, the results of this large retrospective 
study on 234 R/R HL in the real world support the 
effectiveness of BV with a manageable toxicity as 
previously reported also in clinical trials; in particular, our 
report confirms activity also in elderly patients, duration 
of the clinical response unrelated to the consolidation with 
transplant procedure, the relevance of the CR status at first 
restaging for the quality of the final response, and the role 
of BV as a bridge to ASCT for chemorefractory patients.
MATERIALS AND METHODS
An observational retrospective study was conducted 
on patients with R/R HL treated with BV in 40 Italian 
centers outside clinical trials.[29] The study was approved 
by our institutional board (Azienda Ospedaliera di 
Bologna, Policlinico S.Orsola-Malpighi, coordinating 
center) and by all involved Ethical Committees and 
registered in the Italian Registry of Observational 
Studies. All participants gave written informed consent 
in accordance with the Declaration of Helsinki. A shared 
database was used after the approval of all the co-
investigators and variables were strictly defined to avoid 
bias in reporting data. We obtained a special permission 
(for scientific purpose) from our Ethical Committee to 
collect even data of patients who were deceased or lost 
to follow up. 
From November 2012 to July 2014, a total of 234 
patients with R/R HL were treated with BV according 
to the Italian law 648/96. All patients had histologically 
confirmed CD30+ disease; subjects were relapsed 
after prior ASCT or relapsed after at least two lines of 
chemotherapy if not eligible for ASCT due to insufficient 
stem cell collection or chemorefractory disease. 
Patients received a 30-minute infusion of BV at the 
dose of 1.8 mg/kg of body weight every 3 weeks for a 
maximum of 16 cycles. Dose reduction to 1.2 mg/kg was 
recommended in case of grade 3 toxicity. The treatment 
was interrupted in case of grade 4 toxicity. 
The primary endpoint of the study was the best 
response achieved any time during BV therapy; secondary 
endpoints were ORR at the end of the treatment, DoR, 
OS, PFS, DFS, and the incidence and severity of any 
AE occurring during treatment. Effectiveness was also 
evaluated through the occurrence of LTR patients, defined 
as patients who have response (CR or PR) duration ≥12 
months. Response was assessed by PET/CT scan after 
cycle 4, 8, 12 and at drug discontinuation using the 
International Working Group revised response criteria for 
malignant lymphoma.[30] Safety and tolerability were 
evaluated by recording incidence, severity, and type of any 
AE according to the National Cancer Institute Common 
Terminology Criteria for AEs v4.0. 
ORR was defined as the sum of CR and PR rates 
at the end of BV treatment and before any type of 
consolidation. OS was defined as the time from initiation 
of therapy to death from any cause and was censored at the 
date of last available follow up. PFS was measured from 
initiation of therapy to progression, relapse, or death from 
any cause and was censored at the date of last available 
follow up. DFS was calculated for CR patients from the 
first documentation of response to the date of relapse or 
death due to lymphoma or acute toxicity of treatment. DoR 
was calculated from the first objective tumor response (CR 
or PR) to first documentation of progression or death.[30]
Demographics and patients’ characteristics as well 
AEs were summarized by descriptive statistics. Survival 
functions were estimated by using the Kaplan-Meier 
method and were compared using log-rank test. Statistical 
analyses were performed with Stata 11 (StataCorp LP, TX) 
and p values were set at 0.05.
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